Showing results (71-80 of 256) with videos related to
Sort By:
Pageof 26
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|August 18, 2000
[Estimation of adverse drug reactions by the evaluation scores of subjective symptoms (complaints) and background of patients. V. Drug-induced gastrointestinal system disorders]F Ohtsu, R Yano, K Inagaki, et al.Cardiovascular Drugs and Therapy|December 2, 2000
The cardioprotective effects of a new 1,4-benzothiazepine derivative, JTV519, on ischemia/reperfusion-induced Ca2+ overload in isolated rat heartsK Inagaki, Y Kihara, T Izumi, et al.Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 25, 2000
[Estimation of adverse drug reactions by the evaluation scores of subjective symptoms (complaints) and background of patients. III. Drug-induced leucopenia]F Ohtsu, R Yano, K Inagaki, et al.Journal of Experimental Psychology. General|August 16, 2019
Opioids and social bonding: Effect of naltrexone on feelings of social connection and ventral striatum activity to close othersTristen K Inagaki, Laura I Hazlett, Carmen AndreescuJournal of Bioscience and Bioengineering|October 20, 2005
Purification and characterization of an acid trehalase from Acidobacterium capsulatumK Inagaki, N Ueno, T Tamura, et al.Kekkaku : [Tuberculosis]|January 1, 1997
[Surgically unsuccessful cases with pulmonary tuberculosis]M Yano, T Arai, K Inagaki, et al.The Analyst|March 11, 1999
Direct injection determination of theophylline and caffeine in blood serum by high-performance liquid chromatography using an ODS column coated with a zwitterionic bile acid derivativeT Umemura, R Kitaguchi, K Inagaki, et al.Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|February 3, 2000
[Estimation of adverse drug reactions by the evaluation scores of subjective symptoms (complaints) and background of patients. II. Drug-induced extrapyramidal symptoms]F Ohtsu, R Yano, K Inagaki, et al.Journal of Behavioral Medicine|February 22, 2025
Giving support to close others increases affective risk perceptions: longitudinal and experimental studiesMolly Gonenne, Rebecca A Ferrer, Tristen K InagakiCancer Chemotherapy and Pharmacology|January 29, 1999
A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV)R Kizu, T Nakanishi, K Hayakawa, et al.Pageof 26